全球絲裂黴素市場（2023-2030）：規模、份額、增長分析以及按類型（2mg/10mg）和應用（癌症治療/眼科）預測

全球絲裂黴素市場規模將從2021年的1.611億美元增長到2022年的1.757億美元，預測期內復合年增長率為9.1%，到2030年將達到3.622億美元。預計將增長到這一規模美元。

自 1974 年獲得 FDA 批准以來，絲裂黴素已成為一種非常成功的癌症治療藥物，通過抑制 DNA 合成來促進化療和整體治療。 由於全球癌症患者數量大幅增加，需求大幅增加，這種藥物的市場在過去幾年中出現了顯著增長。

從應用來看，癌症治療領域將在 2021 年佔據全球市場的主導地位，並預計在整個預測期內將保持其主導地位。 絲裂黴素已在多種腫瘤類別中顯示出療效，包括胃癌、胰腺癌、乳腺癌、非小細胞肺癌、宮頸癌、前列腺癌和膀胱癌，在臨床上表現出廣泛的抗腫瘤功效。

按地區劃分，亞太地區正在成為絲裂黴素極具吸引力的市場，其中日本是全球領先的主要供應國。 此外，印度產量也大幅增加，亞太市場受益。 領先的製造商正在積極擴大其在該地區的業務，為其在全球市場中日益重要的地位作出貢獻。

本報告調查了全球絲裂黴素市場，並提供了市場概況、市場各種影響因素分析、技術和創新趨勢、法律和監管環境、市場規模趨勢和預測，以及各個細分市場和地區的細分。我們編制了市場細分、競爭格局和主要公司概況。

目錄

執行摘要

調查方法

母公司市場分析

• 市場概覽
• 市場規模
• 市場動態
  • 促進因素
  • 機會
  • 抑制因素
  • 作業

主要市場洞察

• 技術分析
• 價格分析
• 供應鏈分析
• 價值鏈分析
• 市場生態系統
• 知識產權分析
• 貿易分析
• 啟動分析
• 原材料分析
• 創新矩陣
• 管道產品分析
• 宏觀經濟指標
• 主要投資分析
• 關鍵成功因素
• 競爭程度

市場動態與展望

• 市場動態
  • 促進因素
  • 機會
  • 抑制因素
  • 作業
• 監管狀況
• 波特的分析
• Skyquest 對未來顛覆的獨家見解

按類型劃分的全球絲裂黴素市場

• 市場概覽
• 2mg
• 10毫克
• 其他

全球絲裂黴素市場：按應用分類

• 市場概覽
• 癌症治療
• 眼科
• 其他

全球絲裂黴素市場：按地區

• 市場概覽
• 北美
• 歐洲
• 亞太地區
• 拉丁美洲
• 中東/非洲

競爭格局

• 排名前 5 名的公司比較
• 主要公司的市場地位
• 各大公司的招聘策略
• 關鍵成功策略
• 近期市場活動
• 主要公司的市場份額

主要公司簡介

• Kyowa-kirin
• Teva
• Bristol-Myers Squibb
• Aspen Pharmacare
• Kyowa Hakko Kirin Co., Ltd.
• Shanghai Sun-shine Pharmaceutical Technology Co., Ltd.
• Zydus Cadila
• Intas Pharmaceuticals
• Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd.
• Cipla Inc.
• Tianjin Jinyao Group Co., Ltd.
• Jiangsu Hengrui Medicine Co., Ltd.
• Sandoz International GmbH
• Pfizer Inc.
• Chongqing Fuan Pharmaceutical Group Co., Ltd.
• Mylan Pharmaceuticals Inc.
• Hainan Haiyao Co., Ltd.
• Tianjin Takeda Pharmaceuticals Co., Ltd.
• Wockhardt Ltd.
• Dr. Reddy's Laboratories Ltd.
• KKKKK

Global Mitomycin Market size was valued at USD 161.1 million in 2021 and is poised to grow from USD 175.7 million in 2022 to USD 362.2 million by 2030, growing at a CAGR of 9.1% in the forecast period (2023-2030).

Mitomycin is a medication used to treat cancer by impeding the division of active cells through various metabolic influences. The application of this therapeutic drug in cancer treatment is based on the distinction between cancer cells and normal cells in terms of their accelerated cell division, which is attributed to unregulated growth.

Since receiving approval from the FDA in 1974, Mitomycin has emerged as a highly successful cancer treatment, expediting the chemotherapy procedure and overall therapy by obstructing the synthesis of DNA. The global market for this drug has witnessed remarkable expansion in recent times, driven by the significant rise in cancer cases worldwide, leading to a substantial surge in demand.

Top-down and bottom-up approaches were used to estimate and validate the size of Mitomycinand to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined by using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Mitomycin Market Segmental Analysis

Mitomycin Market is segmented based on the Component, Type, Application, and Region. Based on the Type, the Mitomycin Market is segmented as 2mg and 10mg and others. Based on the Application, the Mitomycin Market is segmented as Cancer Treatment, Ophthalmic Use, and others. Based on Region Mitomycin Market is categorized into North America, Europe, Asia-Pacific, Latin America, and MEA.

Mitomycin Market Analysis by Application

In the realm of applications, Cancer treatment took center stage in the global market in 2021 and is expected to maintain its dominance throughout the projected timeframe. Mitomycin exhibits a wide-ranging clinical antitumor effect, displaying efficacy across various tumor categories such as gastric cancer, pancreatic cancer, breast cancer, non-small cell lung cancer, cervical cancer, prostate cancer, and bladder cancer.

Global Mitomycin Market Regional Insights

Asia Pacific is swiftly becoming an attractive market for mitomycin, and Japan is taking the lead as the primary provider of this medication worldwide. Moreover, India is experiencing a substantial rise in mitomycin production, benefiting the Asia Pacific market. Top manufacturers are actively enlarging their presence in this region, contributing to its growing significance in the global market.

Global Mitomycin Market Dynamics

Mitomycin Market Driver

Increasing Ophthalmology Utilization Creates Opportunities for Drugmakers

The increasing occurrence of cancer worldwide has greatly increased the demand for mitomycin. Its affordability has provided it with an edge over other treatment alternatives. Its widespread acceptance is set to rise further, leading to a substantial demand in the foreseeable future. It is extensively utilized in the management of melanoma, colorectal cancer, prostate cancer, lung cancer, blood cancer, breast cancer, and various eye-related conditions, encompassing a diverse range of ophthalmic ailments.

Mitomycin Market Restraint

Increasing cost

Insurance is not included, so the usual price for Mitomycin can be approximately $697.84 or higher. However, with a SingleCare Mitomycin discount card, customers can buy a 1, 20MG Solution Reconstituted of Mitomycin for only $104.62. These convenient discounts can be utilized at popular pharmacies like CVS Pharmacy, Walmart Pharmacy, Walgreens, and Kroger without any issues of plagiarism.

Global Mitomycin Market Competitive Landscape

The level of competition in the global mitomycin market is relatively low, with a small number of key players dominating the industry. These prominent companies, such as Kyowa-kirin, Intas Pharmaceuticals, Speciality European Pharma, Teva Pharmaceuticals, Bristol-Myers Squibb, Rocket Pharmaceuticals, and Aspen, are constantly striving to develop enhanced products that offer highly effective medications to their customers. For instance, Rocket Pharma recently announced the initiation of a phase 2 study for a medicine designed for gene therapy in the treatment of fanconi anaemia, a rare disease. During this trial phase, the focus will primarily be on evaluating the drug's ability to withstand mitomycin C, a chemotherapy agent that causes DNA damage, over a one-year period.

Mitomycin Market Top Player's Company Profiles:

Mitomycin Market Recent Developments

In Feb 2022, UroGen has begun a pivotal single-arm Phase 3 trial for UGN-102, an investigational non-surgical treatment for low-grade intermediate-risk non-muscle invasive bladder cancer. UroGen Pharma Ltd. has begun the Phase 3 ENVISION trial of UGN-102 (mitomycin) for intravesical solution in patients with low-grade, intermediate-risk non-muscle invasive bladder cancer (NMIBC).

In Jan 2022, Kyowa Kirin, located in Tokyo, applied for Japanese licensing of Mitomycin-C (mitomycin) as a topical ocular medication for use in glaucoma surgery.

Global Mitomycin Key Market Trends

At present, there are no ongoing patient assistance programs or manufacturer discounts for Mitomycin. Individuals are advised to reach out directly to the manufacturer of this medication in order to inquire about potential cost-saving opportunities, such as rebates, printable coupons, or free coupon codes.

Mitomycin is prescribed for the treatment of various types of cancers, including stomach cancer and pancreatic cancer. It is important to note that this medication focuses solely on alleviating cancer-related symptoms and does not provide a cure for cancer itself. Its mechanism of action involves diminishing or impeding the growth and dissemination of cancer cells.

Global Mitomycin Market SkyQuest Analysis

SkyQuest's ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Co-relates, and Analyses the Data collected utilizing Primary Exploratory Research backed by robust Secondary Desk research.

Based on our Market Analysis findings, the Global Mitomycin Market demonstrates a considerable level of consolidation and minimal competition. Various companies are actively engaged in research and development efforts, with several promising products in the pipeline. These market leaders are employing diverse strategies to expand their customer base, while also forging innovative partnerships with emerging enterprises, thereby enhancing their market dominance and financial gains.

Table of Contents

Executive Summary

• Market Overview
• Wheel of Fortune

Research Methodology

• Information Procurement
• Secondary & Primary Data Sources
• Market Size Estimation
• Market Assumptions & Limitations

Parent Market Analysis

• Market Overview
• Market Size
• Market Dynamics
  • Drivers
  • Opportunities
  • Restraints
  • Challenges

Key Market Insights

• Technology Analysis
• Pricing Analysis
• Supply Chain Analysis
• Value Chain Analysis
• Ecosystem of the Market
• IP Analysis
• Trade Analysis
• Startup Analysis
• Raw Material Analysis
• Innovation Matrix
• Pipeline Product Analysis
• Macroeconomic Indicators
• Top Investment Analysis
• Key Success Factor
• Degree of Competition

Market Dynamics & Outlook

• Market Dynamics
  • Drivers
  • Opportunities
  • Restraints
  • Challenges
• Regulatory Landscape
• Porters Analysis
  • Competitive rivalry
  • Threat of Substitute Products
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers
• Skyquest Special Insights on Future Disruptions
  • Political Impact
  • Economic Impact
  • Social Impact
  • Technical Impact
  • Environmental Impact
  • Legal Impact

Global Mitomycin Market by Type

• Market Overview
• 2mg
• 10mg
• others

Global Mitomycin Market by Application

• Market Overview
• Cancer Treatment
• Ophthalmic Use
• Others

Global Mitomycin Market Size by Region

• Market Overview
• North America
  • USA
  • Canada
• Europe
  • Germany
  • Spain
  • France
  • UK
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America
  • Brazil
  • Rest of Latin America
• Middle East & Africa (MEA)
  • GCC Countries
  • South Africa
  • Rest of MEA

Competitive Landscape

• Top 5 Player Comparison
• Market Positioning of Key Players, 2021
• Strategies Adopted by Key Market Players
• Top Winning Strategies
  • By Development
  • By Company
  • By Year
• Recent Activities in the Market
• Key Companies Market Share (%), 2021

Key Company Profiles

• Kyowa-kirin
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aspen Pharmacare
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kyowa Hakko Kirin Co., Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Shanghai Sun-shine Pharmaceutical Technology Co., Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zydus Cadila
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Intas Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cipla Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Tianjin Jinyao Group Co., Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Jiangsu Hengrui Medicine Co., Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sandoz International GmbH
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Chongqing Fuan Pharmaceutical Group Co., Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mylan Pharmaceuticals Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hainan Haiyao Co., Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Tianjin Takeda Pharmaceuticals Co., Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Wockhardt Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dr. Reddy's Laboratories Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments